AMCZX
Price
$19.49
Change
+$0.04 (+0.21%)
Updated
Jul 31 closing price
Net Assets
294.35M
PEMGX
Price
$38.86
Change
-$0.30 (-0.77%)
Updated
Jul 31 closing price
Net Assets
23.1B
Interact to see
Advertisement

AMCZX vs PEMGX

AMCZX vs PEMGX Comparison Chart in %
View a ticker or compare two or three
VS
AMCZX vs. PEMGX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMCZX is a Buy and PEMGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PEMGX has more cash in the bank: 23.1B vs. AMCZX (294M). AMCZX (0.00) and PEMGX (0.00) have matching dividends . AMCZX was incepted earlier than PEMGX: AMCZX (11 years) vs PEMGX (21 years). AMCZX (0.92) and PEMGX (0.90) have similar cost to investors . AMCZX is a more actively managed with annual turnover of: 88.64 vs. PEMGX (13.70). PEMGX has a lower initial minimum investment than AMCZX: PEMGX (1000) vs AMCZX (500000). AMCZX annual gain was more profitable for investors over the last year : 8.16 vs. PEMGX (-14.48). PEMGX return over 5 years is better than : -5.82 vs. AMCZX (-14.65).
AMCZXPEMGXAMCZX / PEMGX
Total Expense Ratio0.790.9088%
Annual Report Gross Expense Ratio0.920.90102%
Fund Existence11 years21 years-
Gain YTD4.169-4.591-91%
Front LoadN/A6%-
Min. Initial Investment500000100050,000%
Min. Initial Investment IRAN/AN/A-
Net Assets294M23.1B1%
Annual Yield % from dividends0.000.00-
Returns for 1 year8.16-14.48-56%
Returns for 3 years49.4611.28438%
Returns for 5 years-14.65-5.82252%
Returns for 10 years90.0476.25118%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ESGV132.020.89
+0.68%
Vanguard ESG US Stock ETF
SPMV50.75N/A
N/A
Invesco S&P 500 Minimum Variance ETF
BNDP73.11-0.17
-0.23%
Vanguard Core-Plus Bond Index ETF
NIM9.16-0.03
-0.33%
Nuveen Select Maturities Municipal Fund
HQL19.10-0.34
-1.75%
abrdn Life Sciences Investors